Bexacat: A New Once-Daily Oral Treatment for Feline Diabetes Mellitus

Dr. Cynthia Ward discusses an unique treatment for the management of cats that have been newly diagnosed with diabetes mellitus. Bexacat is not for every diabetic cat, but if appropriate, it can revolutionize feline diabetes treatment by reducing the fear and time involved in treating these cats. Bexacat is the first sodium-glucose cotransporter 2 (SGLT2) inhibitor approved by the FDA in any animal species. Bexacat offers a non-insulin, needle-free, once-daily oral medication specifically designed for cats with diabetes mellitus. This first-in-class therapeutic is indicated to improve glycemic control in otherwise healthy cats with diabetes mellitus not previously treated with insulin. Because it is administered orally, Bexacat can improve convenience for pet owners and increase compliance rates by removing the barriers associated with insulin injections.